Aktuellt
SENASTE
Redeye remains positive on Genovis following a Q2 that showcased 40% sales growth in the analytics business, alongside EBIT margins of 20%. The bioprocess order we expected in Q2 did not materialize, we will reconsider our forecasting approach to accomodate for the uncertainty and difficulty of timing these orders.
LÄS MER
